Grupo Clarin S.A. to Host Webcast Presentation to Discuss Third Quarter 2025 Results
BUENOS AIRES, ARGENTINA / ACCESS Newswire / October 24, 2025 / Grupo Clarín S.A. (BYMA:GCLA)
BUENOS AIRES, ARGENTINA / ACCESS Newswire / October 24, 2025 / Grupo Clarín S.A. (BYMA:GCLA)
BUENOS AIRES, ARGENTINA / ACCESS Newswire / October 24, 2025 / Cablevisión Holding S.A. (BYMA:CVH)(OTC
Led by Eric Sprott and Crescat Capital VANCOUVER, BC / ACCESS Newswire / October 24,
VANCOUVER, BC / ACCESS Newswire / October 24, 2025 / Zimtu Capital Corp. (TSXV:ZC)(FSE:ZCT1) (the
ANAHEIM, CA / ACCESS Newswire / October 24, 2025 / Citrus America, North America’s leading
VANCOUVER, BC / ACCESS Newswire / October 24, 2025 / BeMetals Corp. (TSXV:BMET)(OTCQB:BMTLF)(Frankfurt:1OI.F) (the “Company”
Friends of Jockey Hollow Steps In to Keep Park Open Amid Government Shutdown MORRISTOWN, NEW
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / October 24, 2025 / Totec Resources Ltd.
TORONTO, ONTARIO / ACCESS Newswire / October 24, 2025 / CCL Industries Inc., (TSX:CCL.A, CCL.B)
The Native Sons of the Golden West continue their six-decade legacy of philanthropy with $225,000
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / October 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX)
Senator Joseph M. Neal Jr. Apartments Break Ground; One- and Two-Bedroom Apartments Expected to Open
Exclusive slot titles now live and playable on casino floors at Caesars’ destinations in Atlantic
BEIJING, Oct. 24, 2025 /PRNewswire/ — WiMi Hologram Cloud Inc. (NASDAQ: WiMi) (“WiMi” or the
DALLAS, Oct. 24, 2025 /PRNewswire/ — Powered by AT&T Fiber and 5G, Connectopia is the
First new academic building in nearly 50 years stands as lasting tribute to a visionary
The recognition highlights Profound’s impact in helping global brands gain visibility and control within AI-powered
SASKATOON, SK / ACCESS Newswire / October 24, 2025 / Consumer Choice Award is pleased
The Company holds $50M of cash and approximately 55M BERA, valued at $110M based on
Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments